Key facts
- This page summarizes Versant Venture Capital VI, L.P.'s Form 4 filing for Contineum Therapeutics, Inc. (CTNM).
- 21 reported transactions and 18 derivative rows are listed below.
- Accepted by SEC: 11 Apr 2024, 18:10.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Conversion of derivative security
Additional SEC filing notes
Section 16 status
Versant Venture Capital VI, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Footnote F1
Upon the closing of the Issuer's initial public offering (the "IPO"), such shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock") converted automatically into shares of the Issuer's Class A common stock (the "Class A Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date.
Footnote F2
The shares are held directly by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV GP") is the general partner of VVC IV and disclaims beneficial ownership of the shares held by VVC IV, except to the extent of its pecuniary interest therein.
Footnote F3
The shares are held directly by Versant Side Fund IV, L.P. ("VSF IV"). VV IV GP is the general partner of VSF IV and disclaims beneficial ownership of the shares held by VSF IV, except to the extent of its pecuniary interest therein.
Footnote F4
The shares are held directly by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Each of VV I GP-GP and VV I GP disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.
Footnote F5
The shares are held directly by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.
Footnote F6
In connection with the closing of the IPO, the Reporting Persons elected to have such shares of Preferred Stock convert into shares of the Issuer's Class B common stock (the "Class B Common Stock"), on a one-for-one basis for no additional consideration. The Preferred Stock had no expiration date.
Footnote F7
Each share of the Issuer's Class B Common Stock is convertible into one share of Class A Common Stock at the holder's election, provided that as a result of such conversion, such holder, together with its affiliates, will not beneficially own in excess of 4.99% of the Issuer's Class A Common Stock immediately prior to and following such conversion. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B Common Stock upon 61 days' notice to the Issuer.